Small molecule · Inhibitor of poly(ADP-ribose) polymerase (PARP) (PARP1) · developed by ASTRAZENECA
Saruparib is an orally bioavailable inhibitor of poly(ADP-ribose) polymerase (PARP). It binds PARP and blocks PARP-mediated repair of single-strand DNA breaks through base-excision repair, leading to DNA strand break accumulation and apoptosis. It is being studied in pancreatic ductal adenocarcinoma, metastatic castration-sensitive prostate cancer, and solid tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06713369 | Phase 1 | Locally Advanced or Metastatic Solid Tumor | Recruiting | AZN |
| NCT04005690 | Early Phase 1 | Locally Advanced Pancreatic Ductal Adenocarcinoma | Recruiting | CRDF |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Borderline Resectable Pancreatic Ductal AdenocarcinomaLocally Advanced or Metastatic Solid TumorLocally Advanced Pancreatic Ductal AdenocarcinomaMetastatic Castration-Sensitive Prostate CancerMetastatic Pancreatic Ductal AdenocarcinomaResectable Pancreatic Ductal AdenocarcinomaStage II Pancreatic Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8Unresectable Pancreatic Ductal Adenocarcinoma
Updated Nov 15, 2026. Something wrong or missing? Report it on the AZN page.
See AZN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
AZN catalysts and pipeline →